Mahlich Jörg, Riou Sybille, Verry Matthieu
Miltenyi Biomedicine, Bergisch Gladbach, Germany.
Düsseldorf Institute for Competition Economics (DICE), Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Front Med (Lausanne). 2023 Oct 27;10:1264021. doi: 10.3389/fmed.2023.1264021. eCollection 2023.
When assessing the value of new drugs regulatory authorities across the world frequently make different decisions even though their decisions are based on the same evidence package. In this perspective we argue that even in today's world regulatory and medical decision making is framed by conflicting philosophical schools of thought, namely the liberal tradition of the Anglo Saxon countries pioneered by the Scotsman Adam Smith and the continental European tradition of paternalism that roots back to the German philosopher Georg Friedrich Hegel. We outline the basics of these two philosophical theories and show that countries following the liberal tradition are more reluctant to reject new drugs due to weak evidence. Instead, they leave decisions to a greater extend to those who are affected, namely patients and their caregivers.
在评估新药价值时,尽管世界各地的监管机构依据相同的证据做出决策,但它们常常会做出不同的决定。从这个角度来看,我们认为,即使在当今世界,监管决策和医疗决策也受到相互冲突的哲学思想流派的影响,即由苏格兰人亚当·斯密开创的盎格鲁-撒克逊国家的自由主义传统,以及可追溯到德国哲学家格奥尔格·弗里德里希·黑格尔的欧洲大陆家长式统治传统。我们概述了这两种哲学理论的基本要点,并表明遵循自由主义传统的国家不太愿意因证据不足而拒绝新药。相反,它们在更大程度上把决策权交给受影响的人,即患者及其护理人员。